Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder

66
8
Favorite

Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder

seekingalpha2022-02-07

The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（8）

ppyys
·2022-02-07
Comment and like
Reply
2
Report
MC8989
·2022-02-07
Good
Reply
3
Report
Betterjob
·2022-02-07
Good news
Reply
4
Report
Fold Replies
- indietro_:
  Ok
  2022-02-07
  Reply
  Report
ping23
·2022-02-07
pls like
Reply
5
Report
MandyLow118
·2022-02-07
tq for sharing....
Reply
6
Report
RChia
·2022-02-07
Like please
Reply
2
Report
ValAly
·2022-02-07
Like
Reply
3
Report
plasticbag
·2022-02-07
Ok
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2209378762?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-07 18:53","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2209378762","market":"us","top_or_hot":-1,"title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","media":"seekingalpha","content":"<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","article_id":"2209378762","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","pubTimestamp":1644231186,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特","BK4007":"制药"},"translate_title":"赛诺菲的Enjaymo获得美国FDA罕见血液疾病批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9},"content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9098754648,"gmtCreate":1644242478589,"gmtModify":1676533903211,"author":{"id":"3581756384979769","authorId":"3581756384979769","name":"ppyys","avatar":"https://static.tigerbbs.com/610302822a164d13f68b36645cef259a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581756384979769","authorIdStr":"3581756384979769"},"htmlText":"Comment and like","listText":"Comment and like","text":"Comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098754648","repostId":2209378762,"repostType":4,"repost":{"id":"2209378762","kind":"news","pubTimestamp":1644231186,"share":"https://ttm.financial/m/news/2209378762?lang=&edition=fundamental","pubTime":"2022-02-07 18:53","market":"us","language":"en","title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","media":"seekingalpha","summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) approved <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>&#39;s Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).</p><p>The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body&#39;s immune system attacks the red blood cells and destroy them.</p><p>Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.</p><p>The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.</p><p>Enjaymo is expected to be available in the U.S. in the coming weeks.</p><p>The U.S. list price of Enjaymo is $1,800 per vial.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2209378762","content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098763926,"gmtCreate":1644235064482,"gmtModify":1676533902284,"author":{"id":"3562482274169298","authorId":"3562482274169298","name":"MC8989","avatar":"https://static.tigerbbs.com/58eed81f9dc051542d8569ad3065f505","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3562482274169298","authorIdStr":"3562482274169298"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098763926","repostId":2209378762,"repostType":4,"repost":{"id":"2209378762","kind":"news","pubTimestamp":1644231186,"share":"https://ttm.financial/m/news/2209378762?lang=&edition=fundamental","pubTime":"2022-02-07 18:53","market":"us","language":"en","title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","media":"seekingalpha","summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) approved <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>&#39;s Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).</p><p>The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body&#39;s immune system attacks the red blood cells and destroy them.</p><p>Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.</p><p>The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.</p><p>Enjaymo is expected to be available in the U.S. in the coming weeks.</p><p>The U.S. list price of Enjaymo is $1,800 per vial.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2209378762","content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":633526654,"gmtCreate":1644233120905,"gmtModify":1676532687768,"author":{"id":"4087549167151930","authorId":"4087549167151930","name":"Betterjob","avatar":"https://static.tigerbbs.com/3a6e660c283e305dd2a1669316c2511b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087549167151930","authorIdStr":"4087549167151930"},"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/633526654","repostId":2209378762,"repostType":4,"repost":{"id":"2209378762","kind":"news","pubTimestamp":1644231186,"share":"https://ttm.financial/m/news/2209378762?lang=&edition=fundamental","pubTime":"2022-02-07 18:53","market":"us","language":"en","title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","media":"seekingalpha","summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) approved <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>&#39;s Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).</p><p>The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body&#39;s immune system attacks the red blood cells and destroy them.</p><p>Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.</p><p>The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.</p><p>Enjaymo is expected to be available in the U.S. in the coming weeks.</p><p>The U.S. list price of Enjaymo is $1,800 per vial.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2209378762","content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7233629,"gmtCreate":1644234252474,"gmtModify":1663239753726,"authorId":3586255748151463,"author":{"id":3586255748151463,"idStr":"3586255748151463","authorId":3586255748151463,"name":"indietro_","avatar":"https://static.tigerbbs.com/caebb6c2a70cbd2db563a3808f3d7b22","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":633526654,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":9098781076,"gmtCreate":1644232408174,"gmtModify":1676533902061,"author":{"id":"3574521189147374","authorId":"3574521189147374","name":"ping23","avatar":"https://static.tigerbbs.com/c38fda829a130d716804cbae538a7cb8","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574521189147374","authorIdStr":"3574521189147374"},"htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098781076","repostId":2209378762,"repostType":4,"repost":{"id":"2209378762","kind":"news","pubTimestamp":1644231186,"share":"https://ttm.financial/m/news/2209378762?lang=&edition=fundamental","pubTime":"2022-02-07 18:53","market":"us","language":"en","title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","media":"seekingalpha","summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) approved <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>&#39;s Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).</p><p>The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body&#39;s immune system attacks the red blood cells and destroy them.</p><p>Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.</p><p>The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.</p><p>Enjaymo is expected to be available in the U.S. in the coming weeks.</p><p>The U.S. list price of Enjaymo is $1,800 per vial.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2209378762","content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098789368,"gmtCreate":1644231978177,"gmtModify":1676533902027,"author":{"id":"4088156876983060","authorId":"4088156876983060","name":"MandyLow118","avatar":"https://static.tigerbbs.com/4f2481989f5fe021a34d2e24b5102138","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4088156876983060","authorIdStr":"4088156876983060"},"htmlText":"tq for sharing....","listText":"tq for sharing....","text":"tq for sharing....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098789368","repostId":2209378762,"repostType":4,"repost":{"id":"2209378762","kind":"news","pubTimestamp":1644231186,"share":"https://ttm.financial/m/news/2209378762?lang=&edition=fundamental","pubTime":"2022-02-07 18:53","market":"us","language":"en","title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","media":"seekingalpha","summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) approved <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>&#39;s Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).</p><p>The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body&#39;s immune system attacks the red blood cells and destroy them.</p><p>Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.</p><p>The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.</p><p>Enjaymo is expected to be available in the U.S. in the coming weeks.</p><p>The U.S. list price of Enjaymo is $1,800 per vial.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2209378762","content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098780512,"gmtCreate":1644231818004,"gmtModify":1676533902011,"author":{"id":"3576295472948618","authorId":"3576295472948618","name":"RChia","avatar":"https://static.tigerbbs.com/cea89db323c5328650526772cf80ec19","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576295472948618","authorIdStr":"3576295472948618"},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098780512","repostId":2209378762,"repostType":4,"repost":{"id":"2209378762","kind":"news","pubTimestamp":1644231186,"share":"https://ttm.financial/m/news/2209378762?lang=&edition=fundamental","pubTime":"2022-02-07 18:53","market":"us","language":"en","title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","media":"seekingalpha","summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) approved <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>&#39;s Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).</p><p>The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body&#39;s immune system attacks the red blood cells and destroy them.</p><p>Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.</p><p>The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.</p><p>Enjaymo is expected to be available in the U.S. in the coming weeks.</p><p>The U.S. list price of Enjaymo is $1,800 per vial.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2209378762","content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098780118,"gmtCreate":1644231742880,"gmtModify":1676533902011,"author":{"id":"3562707747643111","authorId":"3562707747643111","name":"ValAly","avatar":"https://static.tigerbbs.com/9d97b7d80605b322b36bcb7e5b0dff4f","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3562707747643111","authorIdStr":"3562707747643111"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098780118","repostId":2209378762,"repostType":4,"repost":{"id":"2209378762","kind":"news","pubTimestamp":1644231186,"share":"https://ttm.financial/m/news/2209378762?lang=&edition=fundamental","pubTime":"2022-02-07 18:53","market":"us","language":"en","title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","media":"seekingalpha","summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) approved <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>&#39;s Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).</p><p>The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body&#39;s immune system attacks the red blood cells and destroy them.</p><p>Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.</p><p>The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.</p><p>Enjaymo is expected to be available in the U.S. in the coming weeks.</p><p>The U.S. list price of Enjaymo is $1,800 per vial.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2209378762","content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9098717519,"gmtCreate":1644231582199,"gmtModify":1676533902002,"author":{"id":"3585042599146244","authorId":"3585042599146244","name":"plasticbag","avatar":"https://static.tigerbbs.com/75759bfc97d94798a8f93df583a58523","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585042599146244","authorIdStr":"3585042599146244"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098717519","repostId":2209378762,"repostType":4,"repost":{"id":"2209378762","kind":"news","pubTimestamp":1644231186,"share":"https://ttm.financial/m/news/2209378762?lang=&edition=fundamental","pubTime":"2022-02-07 18:53","market":"us","language":"en","title":"Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2209378762","media":"seekingalpha","summary":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease ","content":"<html><head></head><body><p>The U.S. Food and Drug Administration (FDA) approved <a href=\"https://laohu8.com/S/SNY\">Sanofi</a>&#39;s Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).</p><p>The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body&#39;s immune system attacks the red blood cells and destroy them.</p><p>Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.</p><p>The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.</p><p>Enjaymo is expected to be available in the U.S. in the coming weeks.</p><p>The U.S. list price of Enjaymo is $1,800 per vial.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Enjaymo Wins US FDA Approval for Rare Blood Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-07 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD...</p>\n\n<a href=\"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3796359-sanofis-enjaymo-wins-us-fda-approval-for-rare-blood-disorder","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2209378762","content_text":"The U.S. Food and Drug Administration (FDA) approved Sanofi's Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).The company said Enjaymo became the first and only approved treatment for people with CAD — a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). The body's immune system attacks the red blood cells and destroy them.Sanofi said CAD is a chronic and rare blood disorder that affects nearly 5K people in the U.S.The approval was backed by data from a phase 3 trial, dubbed, CARDINAL.Enjaymo is expected to be available in the U.S. in the coming weeks.The U.S. list price of Enjaymo is $1,800 per vial.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":66,"commentSize":8,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}